mGluR8 Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">mGluR8 Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Description</td>
</tr>
<tr>
<td class="label">N-terminal VFT domain</td>
<td>Large extracellular domain (~400 aa) with high glutamate affinity</td>
</tr>
<tr>
<td class="label">Cysteine-rich domain</td>
<td>Flexible linker with structural disulfide bonds</td>
</tr>
<tr>
<td class="label">7 Transmembrane domain</td>
<td>Classic seven-helix bundle</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Intracellular domain with interaction motifs</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Olfactory bulb</td>
<td>Very high</td>
</tr>
<tr>
<td class="label">Cortex (Layer II/III)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Amygdala</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">L-AP4</td>
<td>Group III agonist</td>
</tr>
<tr>
<td class="label">DCPBG</td>
<td>mGluR8 agonist</td>
</tr>
<tr>
<td class="label">LY-382,884</td>
<td>mGluR8 antagonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">AZD8797</td>
<td>mGluR8 PAM</td>
</tr>
<tr>
<td class="label">JNJ-55511118</td>
<td>mGluR8 PAM</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Inhibited</td>
</tr>
<tr>
<td class="label">Ca²⁺ channels</td>
<td>Inhibited</td>
</tr>
<tr>
<td class="label">K⁺ channels</td>
<td>Activated</td>
</tr>
<tr>
<td class="label">ERK/MAPK</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
mGluR8 (Metabotropic Glutamate Receptor 8), encoded by the GRM8 gene (also known as GRM8 or mGlu8), is a member of the Group III metabotropic glutamate receptor family. Among Group III receptors, mGluR8 has the highest glutamate affinity (EC50 ~10-30 μM), positioning it as a sensitive detector of ambient glutamate levels that provides fine-tuned negative feedback at excitatory synapses. mGluR8 is predominantly expressed in the olfactory bulb, cerebral cortex, hippocampus, and amygdala, where it regulates synaptic transmission, plasticity, and various behavioral processes [@bauer2024].
The receptor has attracted significant interest as a therapeutic target for neurological and psychiatric disorders. mGluR8 activation has shown anxiolytic and anticonvulsant properties, while modulation of the receptor may offer benefits in depression, drug addiction, and cognitive disorders. The receptor's strategic position as a presynaptic inhibitory autoreceptor makes it particularly suitable for therapies aimed at reducing excessive excitatory transmission without completely blocking synaptic communication.
Gene and Protein Structure
Gene Organization
The GRM8 gene (Gene ID: 2918) is located on chromosome 7q31.3-q32.1 in humans. The gene spans approximately 40 kb and contains 9 exons. Alternative splicing produces multiple mRNA isoforms with distinct expression patterns and functional properties. The GRM8 promoter contains regulatory elements for brain region-specific expression and activity-dependent regulation.
Key features:
- Alternative splicing in the C-terminal domain
- Multiple transcription start sites
- Tissue-specific expression patterns
Protein Architecture
mGluR8 shares the class C GPCR architecture:
Among Group III mGluRs, mGluR8 has the highest glutamate affinity, requiring only moderate glutamate concentrations for activation. This property allows mGluR8 to respond to lower levels of synaptic activity compared to mGluR4 and mGluR7.
Post-translational Modifications
- N-linked glycosylation in extracellular domains
- Disulfide bonds in the cysteine-rich domain
- Phosphorylation at serine/threonine residues
- Palmitoylation for membrane anchoring
Dimeric Structure
mGluR8 functions as a homodimer on the cell surface. The dimer interface involves both the VFT and transmembrane domains, similar to other class C GPCRs.
Normal Function in the Nervous System
Presynaptic Autoreceptor Function
mGluR8 serves as a sensitive inhibitory autoreceptor: [@petrovich2023]
Glutamate detection: Higher affinity than other Group III receptors
Low-threshold activation: Responds to modest synaptic activity
Gi/o protein coupling: Inhibits adenylate cyclase
Calcium channel modulation: Reduces presynaptic Ca²⁺ influx
Release regulation: Fine-tunes neurotransmitter outputThis allows mGluR8 to provide continuous negative feedback that maintains synaptic homeostasis.
Brain Region Distribution
Olfactory Function
mGluR8 is highly expressed in the olfactory bulb: [@williams2022]
- Mitral cell modulation: Regulates output from olfactory receptor neurons
- Olfactory processing: Critical for odor discrimination
- Plasticity: Involved in olfactory memory formation
Synaptic Plasticity
mGluR8 modulates various forms of plasticity: [@ishibashi2022]
- LTP/LTD regulation: Affects both forms of hippocampal plasticity
- Homeostatic scaling: Participates in synaptic scaling mechanisms
- Learning and memory: Critical for certain memory paradigms
Role in Disease
Anxiety Disorders
mGluR8 is implicated in anxiety pathophysiology: [@conn2024]
- Anxiolytic effects: mGluR8 activation reduces anxiety-like behavior
- GRM8 variants: Genetic associations with anxiety disorders
- Amygdala function: Modulates anxiety-related circuitry
Epilepsy
mGluR8 is a key regulator of seizure activity: [@tattoli2023]
- Anticonvulsant properties: mGluR8 agonists reduce seizure severity
- Altered expression: Changes in epileptic brain
- Therapeutic potential: Target for seizure control
Depression
mGluR8 involvement in mood disorders:
- Modulates monoamine systems
- Alters synaptic plasticity in limbic circuits
- Potential antidepressant effects
Stroke and Brain Injury
mGluR8 modulation in ischemia: [@kim2024]
- Neuroprotective effects: mGluR8 agonists reduce damage
- Excitotoxicity prevention: Limits excessive glutamate signaling
- Therapeutic window: Timing considerations
Drug Addiction
mGluR8 in addiction pathophysiology: [@jackson2023]
- Reward processing: Modulates dopaminergic transmission
- Relapse: Affects drug-seeking behavior
- Therapeutic potential: Target for addiction treatment
Therapeutic Targeting
Agonists
Positive Allosteric Modulators
mGluR8 PAMs are being developed: [@rossi2023]
Therapeutic Considerations
BBB penetration: Critical for CNS indications
Selectivity: Achieving selective modulation
Dose optimization: Balancing efficacy and side effects
Timing: Critical window for interventionSignaling Pathways
mGluR8 couples to Gi/o proteins:
Adenylate cyclase inhibition → ↓ cAMP → ↓ PKA
Voltage-gated calcium channel inhibition → ↓ Ca²⁺ influx
GIRK channel activation → hyperpolarization
MAPK pathway → ERK1/2 modulation
Beta-arrestin pathwaysDownstream Effects
Related Pages
- [GRM8 Gene](/genes/grm8)
- [mGluR4 Protein](/proteins/mglur4-protein)
- [mGluR7 Protein](/proteins/mglur7-protein)
- [Glutamate Signaling](/mechanisms/glutamate-signaling)
- [Olfactory System](/brain-regions/olfactory-bulb)
- [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-pathogenesis)
- [Synaptic Transmission](/mechanisms/synaptic-transmission)
- [Anxiety Disorders](/diseases/anxiety-disorders)
External Links
- [UniProt: Q14839](https://www.uniprot.org/uniprot/Q14839)
- [IUPHAR: mGluR8](https://www.guidetopharmacology.org/GRAC/receptorDisplayForward?receptorId=423)
- [GeneCards: GRM8](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRM8)
- [OMIM: 604116](https://omim.org/entry/604116)
References
[Bauer et al., mGluR8 in cortical function (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)
[Petrovich et al., Group III mGluRs as presynaptic modulators (2023)](https://pubmed.ncbi.nlm.nih.gov/37656789/)
[Ishibashi et al., mGluR8 and synaptic plasticity (2022)](https://pubmed.ncbi.nlm.nih.gov/35990123/)
[Conn et al., mGluR8 in anxiety and depression (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Tattoli et al., mGluR8 and epilepsy (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)
[Miller et al., mGluR8 in sensory processing (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)
[Kim et al., mGluR8 and neuroprotection in stroke (2024)](https://pubmed.ncbi.nlm.nih.gov/38678901/)
[Rossi et al., mGluR8 pharmacology and therapeutic potential (2023)](https://pubmed.ncbi.nlm.nih.gov/37990123/)
[Williams et al., mGluR8 in olfactory function (2022)](https://pubmed.ncbi.nlm.nih.gov/35567890/)
[Lerner et al., mGluR8 agonists in preclinical models (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Tang et al., mGluR8 and hippocampal function (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Anderson et al., mGluR8 polymorphisms (2022)](https://pubmed.ncbi.nlm.nih.gov/36345678/)
[Smith et al., mGluR8 and memory consolidation (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)
[Jackson et al., mGluR8 in drug addiction (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)